MAPK3 and diabetes mellitus: CaD/enalapril treatment decreased p-VEGFR2 level in the kidney compared to the vehicle-treated diabetic mice (Fig 8A) and significantly suppressed diabetes-induced ERK1/2 (Fig 8B, lane 4 and column 4) and P38 phosphorylation (Fig 8C).